These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 35895102)

  • 1. Comparison of originator and biosimilar monoclonal antibodies using HRMS, Fc affinity chromatography, and 2D-HPLC.
    Reinders LMH; Klassen MD; Teutenberg T; Jaeger M; Schmidt TC
    Anal Bioanal Chem; 2022 Sep; 414(23):6761-6769. PubMed ID: 35895102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physicochemical and functional comparability between the proposed biosimilar rituximab GP2013 and originator rituximab.
    Visser J; Feuerstein I; Stangler T; Schmiederer T; Fritsch C; Schiestl M
    BioDrugs; 2013 Oct; 27(5):495-507. PubMed ID: 23649935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of originator and biosimilar therapeutic monoclonal antibodies using comprehensive two-dimensional liquid chromatography coupled with time-of-flight mass spectrometry.
    Sorensen M; Harmes DC; Stoll DR; Staples GO; Fekete S; Guillarme D; Beck A
    MAbs; 2016 Oct; 8(7):1224-1234. PubMed ID: 27362833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simultaneous Monitoring of Monoclonal Antibody Variants by Strong Cation-Exchange Chromatography Hyphenated to Mass Spectrometry to Assess Quality Attributes of Rituximab-Based Biotherapeutics.
    Di Marco F; Berger T; Esser-Skala W; Rapp E; Regl C; Huber CG
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hydrophilic Interaction Chromatography Hyphenated with Mass Spectrometry: A Powerful Analytical Tool for the Comparison of Originator and Biosimilar Therapeutic Monoclonal Antibodies at the Middle-up Level of Analysis.
    D'Atri V; Fekete S; Beck A; Lauber M; Guillarme D
    Anal Chem; 2017 Feb; 89(3):2086-2092. PubMed ID: 28208257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of Structural and Functional Comparability of Biosimilar Products: Trastuzumab as a Case Study.
    Joshi S; Rathore AS
    BioDrugs; 2020 Apr; 34(2):209-223. PubMed ID: 31975160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glycosylation of biosimilars: Recent advances in analytical characterization and clinical implications.
    Duivelshof BL; Jiskoot W; Beck A; Veuthey JL; Guillarme D; D'Atri V
    Anal Chim Acta; 2019 Dec; 1089():1-18. PubMed ID: 31627805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery and characterization of antibody variants using mass spectrometry-based comparative analysis for biosimilar candidates of monoclonal antibody drugs.
    Li W; Yang B; Zhou D; Xu J; Ke Z; Suen WC
    J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Jul; 1025():57-67. PubMed ID: 27214604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Demonstrating Analytical Similarity of Trastuzumab Biosimilar HLX02 to Herceptin
    Xie L; Zhang E; Xu Y; Gao W; Wang L; Xie MH; Qin P; Lu L; Li S; Shen P; Jiang W; Liu S
    BioDrugs; 2020 Jun; 34(3):363-379. PubMed ID: 32072477
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of biosimilarity under native and heat-stressed conditions: rituximab, bevacizumab, and trastuzumab originators and biosimilars.
    Kang J; Halseth T; Vallejo D; Najafabadi ZI; Sen KI; Ford M; Ruotolo BT; Schwendeman A
    Anal Bioanal Chem; 2020 Jan; 412(3):763-775. PubMed ID: 31853605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The criticality of high-resolution N-linked carbohydrate assays and detailed characterization of antibody effector function in the context of biosimilar development.
    Brady LJ; Velayudhan J; Visone DB; Daugherty KC; Bartron JL; Coon M; Cornwall C; Hinckley PJ; Connell-Crowley L
    MAbs; 2015; 7(3):562-70. PubMed ID: 25898160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of glycoprofiles of rituximab versions licensed for sale in India and an analytical approach for quality assessment.
    Kaur T; Shukla BN; Yadav VK; Kulkarni MJ; Rao A
    J Proteomics; 2021 Jul; 244():104267. PubMed ID: 34015520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cutting-edge mass spectrometry characterization of originator, biosimilar and biobetter antibodies.
    Beck A; Debaene F; Diemer H; Wagner-Rousset E; Colas O; Van Dorsselaer A; Cianférani S
    J Mass Spectrom; 2015 Feb; 50(2):285-97. PubMed ID: 25800010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An Integrated Approach for a Structural and Functional Evaluation of Biosimilars: Implications for Erythropoietin.
    Gianoncelli A; Bonini SA; Bertuzzi M; Guarienti M; Vezzoli S; Kumar R; Delbarba A; Mastinu A; Sigala S; Spano P; Pani L; Pecorelli S; Memo M
    BioDrugs; 2015 Aug; 29(4):285-300. PubMed ID: 26334631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Physicochemical and Biological Characterization of RTXM83, a New Rituximab Biosimilar.
    Cerutti ML; Pesce A; Bès C; Seigelchifer M
    BioDrugs; 2019 Jun; 33(3):307-319. PubMed ID: 30927214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analytical comparability study of anti-CD20 monoclonal antibodies rituximab and obinutuzumab using a stability-indicating orthogonal testing protocol: Effect of structural optimization and glycoengineering.
    Trabik YA; Moenes EM; Al-Ghobashy MA; Nebsen M; Ayad MF
    J Chromatogr B Analyt Technol Biomed Life Sci; 2020 Nov; 1159():122359. PubMed ID: 32920338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative Efficacy and Safety of Biosimilar Rituximab and Originator Rituximab in Rheumatoid Arthritis and Non-Hodgkin's Lymphoma: A Systematic Review and Meta-analysis.
    Lee S; Lee H; Kim E
    BioDrugs; 2019 Oct; 33(5):469-483. PubMed ID: 31446557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How Similar Is Biosimilar? A Comparison of Infliximab Therapeutics in Regard to Charge Variant Profile and Antigen Binding Affinity.
    Beyer B; Walch N; Jungbauer A; Lingg N
    Biotechnol J; 2019 Apr; 14(4):e1800340. PubMed ID: 30315690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Microfluidic capillary electrophoresis - mass spectrometry for rapid charge-variant and glycoform assessment of monoclonal antibody biosimilar candidates.
    Cageling R; Carillo S; Boumeester AJ; Lubbers-Geuijen K; Bones J; Jooß K; Somsen GW
    J Pharm Biomed Anal; 2024 Sep; 248():116301. PubMed ID: 38901155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and effectiveness of biosimilar of Rituximab CT-P10 in the treatment of cryoglobulinemic vasculitis: the MARBLe study (Mixed cryoglobulinemiA Rituximab BiosimiLar).
    Vacchi C; Visentini M; Gragnani L; Fraticelli P; Tavoni A; Filippini D; Saccardo F; Lauletta G; Colantuono S; Atzeni F; Pioltelli P; Manfredi A; Casato M; Zignego AL; Monti G; Pietrogrande M; Galli M; Sebastiani M
    Intern Emerg Med; 2021 Jan; 16(1):149-156. PubMed ID: 32524338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.